October 12, 2016 – This is a communication from Health Canada, issued in May 2016, concerning the danger of reactivation of hepatitis B virus (HBV) infection in patients treated with BCR-ABL tyrosine kinase inhibitors (TKIs) and geared towards healthcare professionals (medical …

BCR-ABL Tyrosine Kinase Inhibitors: Danger of HBV-Reactivation Read more »

July 26, 2016  – Renal cell carcinoma is the most common form of kidney cancer in adults. Advanced renal cell carcinoma includes both metastatic disease and locally advanced renal cell carcinoma that cannot be removed by surgery. Despite the recent …

Cabometyx and Kisplyx: Two new medicines for advanced kidney cancer Read more »

February 07, 2016 – The European Commission has approved once-daily Osimertinib (Tagrissa) for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) that is positive for the epidermal growth-factor receptor (EGFR) T790M mutation. This follows a positive review in …

Osimertinib (Tagrissa) approved for non-smal cell lung cancer (NSCLC) patient subgroup carrying the EGFR T790M mutation Read more »